Volume 53, Issue 6, Pages 1236-1244 (June 2008) A Randomised, Placebo-Controlled Study to Assess the Efficacy of Twice-Daily Vardenafil in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia  Christian G. Stief, Hartmut Porst, Dieter Neuser, Manfred Beneke, Ernst Ulbrich  European Urology  Volume 53, Issue 6, Pages 1236-1244 (June 2008) DOI: 10.1016/j.eururo.2008.01.075 Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 1 Flowchart showing patients’ progress throughout the study. European Urology 2008 53, 1236-1244DOI: (10.1016/j.eururo.2008.01.075) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 2 The least square mean International Prostate Symptom Score (IPSS) total score for the vardenafil and placebo groups (intention-to-treat [ITT] population). A reduced score indicates an improvement in lower urinary tract symptoms (LUTS). * The p value indicates a significant change from baseline for vardenafil versus placebo as analysed with the use of analysis of covariance. European Urology 2008 53, 1236-1244DOI: (10.1016/j.eururo.2008.01.075) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 3 The least square mean International Prostate Symptom Score (IPSS) obstructive (a) and irritative (b) subscores for the vardenafil and placebo groups (intention-to-treat [ITT] population). A reduced score indicates an improvement in lower urinary tract symptoms (LUTS). * The p values indicate a nominally significant change from baseline for vardenafil versus placebo as analysed with the use of analysis of covariance. European Urology 2008 53, 1236-1244DOI: (10.1016/j.eururo.2008.01.075) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 4 The least square mean erectile function domain score of the International Index of Erectile Function (IIEF-EF) score for the vardenafil and placebo groups in (intention-to-treat [ITT] population). An increased score indicates an improvement erectile function. * The p value indicates a nominally significant change from baseline for vardenafil versus placebo as analysed with the use of analysis of covariance. European Urology 2008 53, 1236-1244DOI: (10.1016/j.eururo.2008.01.075) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 5 The least square mean Urolife QoL-9 total score (a), “well-being” score (b), “interference with activities” score (c), and “perceived sexual life” score (d) for the vardenafil and placebo groups (intention-to-treat [ITT] population). An increased score indicates an improvement in quality of life (QoL). * The p values indicate whether there was a nominally significant change from baseline for vardenafil versus placebo as analysed with the use of analysis of covariance. European Urology 2008 53, 1236-1244DOI: (10.1016/j.eururo.2008.01.075) Copyright © 2008 European Association of Urology Terms and Conditions